Inhaled insulin: Take a deep breath, but how?

Journal of Diabetes Science and Technology

Volumn 2, Issue 2, 2008, Pages 297-299

  Heinemann, Lutz ^a   Scheuch, Gerhard ^b   Heise, Tim ^a  

^a PROFIL Institut für Stoffwechselforschung   (Germany)

^b Activaero   (Germany)

Author keywords

Inhalation procedure; Inhaled insulin; Insulin administration; Insulin therapy

Indexed keywords

EID: 79953179882     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680800200222     Document Type: Review

References (16)

1. Farr SJ, McElduff A, Mather LE, Okikawa J, Ward ME, Gonda I, Licko V, Rubsamen RM. Pulmonary insulin administration using the AERx system: physicochemical and physiological factors influencing insulin effectiveness in healthy fasting subjects.. Diabetes Technol Ther. 2000;2(2):185-97.
2. Patton J, Byron P. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67-74.
3. Agnew JE, Pavia D, Clarke SW. Factors affecting the 'alveolar deposition' of 5 microns inhaled particles in healthy subjects. Clin Phys Physiol Meas. 1985;6(1):27-36.
4. Bennett WD. Targeting respiratory drug delivery with aerosol boluses: a review. J Aerosol Med. 1991;4:69-72.
5. Brand P, Friemel I, Meyer T, Schulz H, Heyder J, Häubetainger K. Total deposition of therapeutic particles during spontaneous and controlled inhalations. J Pharm Sci. 2000;89(6):724-31.
6. ICRP Publication 66. Human respiratory tract model for radiological protection. New York: Elsevier Science. Ann ICRP 24:1-120;1994.
7. Nikander K, Denyer J, Smith N, Wollmer P. Breathing patterns and aerosol delivery: impact of regular human patterns, and sine and square waveforms on rate of delivery.. J Aerosol Med. 2001;14(3):327-33.
8. Pavia D, Thomson ML, Clarke SW, Shannon HS. Effect of lung function and mode of inhalation on penetration of aerosol into the human lung. Thorax. 1977;32(2):194-7.
9. Schulz H, Brand P, Heyder J. Particle deposition in the respiratory tract. New York: Dekker; 2000.
10. Whelan AM, Hahn NW. Optimizing drug delivery from metereddose inhalers. DICP. 1991;25(6):638-45.
11. Brand P, Beckmann H, Maas-Enriquez M, Meyer T, Müllinger B, Sommerer K, Weber N, Weuthen T, Scheuch G. Peripheral deposition of alpha 1-protease inhibitor using commercial inhalation devices. Eur Respir J. 2003;22(2):263-7.
12. Scheuch G, Brand P, Meyer T, Muellinger B, Sommerer K. Regional drug targeting within the lungs by controlled inhalation with the AKITA-inhalation system.. Respir Drug Del. 2002; VIII: 471-3.
13. Sommerer K, Meyer T, Brand P, Muellinger B, Pohner A, Weber N, Beckmann H, Maas-Enriquez M, Scheuch G. A strategy to optimize peripheral lung deposition in patients with emphysema. Respir Drug Del. 2002; VIII: 475-8.
14. Rave K, Bott S, Heinemann L, Sha S, Becker RH, Willavize SA, Heise T. Time-action profile of inhaled insulin (Exubera) in comparison with subcutaneously-injected insulin Lispro and regular human insulin.. Diabetes Care. 2005;28(5):1077-82.
15. Mayor S. Inhaled insulin no longer recommended as routine diabetes treatment. BMJ. 2006;333(7557):14.
16. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther. 2002;4(5):673-82.